课题基金 / 基金详情

B43-PAP IMMUNOTOXIN COMBINED WITH STANDARD 4 DRUG INDUCTION FOR CD+ ALL

B43-PAP IMMUNOTOXIN COMBINED WITH STANDARD 4 DRUG INDUCTION FOR CD+ ALL
B43-PAP 免疫毒素与标准 4 药物诱导相结合治疗 CD ALL
批准号：
6274718
负责人：
RAYMOND J HUTCHINSON
金额：
$2.15万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6274718
关键词：
CD antigens acute lymphocytic leukemia antineoplastics asparaginase child (0-11) clinical research clinical trials combination cancer therapy drug screening /evaluation human subject human therapy evaluation immunoconjugates immunotoxicity monoclonal antibody neoplasm /cancer chemotherapy pediatric neoplasm /cancer pediatric pharmacology prednisone

项目摘要

项目成果

RAYMOND J HUTCHINSON的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
CCG 0957 is a phase-I study to determine the toxicity of B43-PAP when given concurrently with a standard four drug re-induction (Vincristine, Prednisone, L'Asparaginase, Daunomycin) in pediatric patients with acute lymphoblastic leukemia (ALL). B43-PAP is an immunotoxin (monoclonal antibody-toxin conjugate) which has been studied for the past 9 years by Dr. Fatih Uckun at the Children's Cancer Group Immunotoxin Resource Laboratory in Minneapolis. Single institution studies have been done at the University of Minnesota. B43 is the monoclonal antibody selected for the protocol because it is targeted toward the CD19 antigen, which displays specificity for pre-B lineage ALL - the most common type of leukemia in children.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Effect of recipient age /graft vs host disease post BMT
VACCINE THERAPY OF PEDIATRIC MALIGNANCIES UTILIZING DENDRITIC CELLS
VACCINE THERAPY OF PEDIATRIC MALIGNANCIES UTILIZING DENDRITIC CELLS
CONTINUOUS 21 DAY INFUSION OF TOPOTECAN IN CHILDREN WITH RELAPSED SOLID TUMORS
海外基金